Floatz logo

Darinaparsin

Peripheral T-cell Lymphoma

Solasia Pharma K.K.Small moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Peripheral T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Darinaparsin is also rated in:

hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
57 / 100
View asset →
bone marrow neoplasmDormant
B
Indicative ·
57 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →